Physician profile
Francesca M Rogers
NPI 1568521912
$3,787.17
in general payments reported to CMS, 2019-2025
24 companies · $462 in 2025
The $462 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $386 · 2021: $747 · 2022: $448 · 2023: $152 · 2024: $1,130 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Food and Beverage | $543.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,243.73 | 2019-2023 | Ubrelvy, Lo Loestrin Fe |
| Mimedx Group, INC. | $1,200.00 | 2024-2025 | Bovine Collagen |
| Exeltis, USA INC. | $162.03 | 2019-2024 | Slynd |
| Therapeuticsmd, INC. | $153.67 | 2019-2021 | |
| Myovant Sciences INC. | $117.80 | 2021-2022 | |
| Sage Therapeutics, LLC | $111.57 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $107.19 | 2020-2025 | Solosec, Phexx, Phexxi |
| Sumitomo Pharma America, INC. | $102.03 | 2023-2025 | Myfembree |
| Bausch Health US, LLC | $89.50 | 2020-2021 | |
| Hologic Sales and Service, LLC | $83.82 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $65.98 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $44.98 | 2021-2022 | |
| Lupin INC. | $42.35 | 2020 | |
| Mission Pharmacal Company | $40.95 | 2019 | |
| Allergan, INC. | $38.39 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $32.75 | 2024 | |
| Supernus Pharmaceuticals, INC. | $28.74 | 2025 | Qelbree |
| Viiv Healthcare Company | $20.77 | 2025 | Apretude |
| Agile Therapeutics, INC. | $18.91 | 2022 | |
| Channel Medsystems, INC. | $18.60 | 2022 | |
| Avion Pharmaceuticals | $17.10 | 2023 | Balcoltra |
| Coopersurgical, INC. | $16.51 | 2020 | |
| Becton, Dickinson and Company | $16.18 | 2023 | Bd Onclarity |
| Astellas Pharma US INC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.